Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Pharmacovigilance

Pharmaceutical companies vow to improve monitoring of medicine side effects

Pharmaceutical companies have agreed to work together on improved ways to identify and monitor adverse drug reactions.

On 28 March 2018, the newly formed International Working Group on Signal Detection and Management in Pharmacovigilance held its inaugural meeting in London, attended by representatives from 20 companies and academic institutions, including Pfizer and Roche.

In pharmacovigilance terms, “signal detection” means interpreting and documenting data on adverse reactions. The data come from multiple sources, including clinical trials, literature reviews and spontaneous reports of adverse reactions.

The working group, which will be managed under the auspices of the Drug Safety Research Unit (DSRU) Centre for Methods and Evidence in Pharmacovigilance, an independent academic unit and registered charity aligned to the University of Portsmouth’s School of Pharmacy and Biomedical Sciences. The group’s aim is to improve signal detection by making better use of advanced tools like big data and artificial intelligence.

Saad Shakir, director of DSRU and chair of the new working group, said: “For the public, this project is about identifying and monitoring adverse reactions more effectively by using new methods. Our aim is for safer, more effective medicines.”

“The last major report and recommendations on signal detection were in 2010 and a lot has changed since then,” Shakir added.

“Big data is becoming increasingly available, artificial intelligence and machine thinking are being included in broad areas of biomedical science and our knowledge of genetics and the relationship between genes and adverse reactions has also improved immensely in recent years.

“We need to look at what the pros and cons are of incorporating these changes — and others — to the process of signal detection and management to ensure we make the best use of new information to better protect patients from the side effects of medicines.”

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2019.20206392

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.